Royalty Pharma plc RPRX

NAS: RPRX | ISIN: GB00BMVP7Y09 26/04/2024

28,00 USD (-0,39%)

(-0,39%) 26/04/2024

Grafiek Royalty Pharma plc

Grafiek Royalty Pharma plc

1 dag1d -0,39%
1 week1w 0,65%
1 maand1m -6,35%
3 maanden3m -3,61%
6 maanden6m 4,87%
1 jaar1j -20,75%
5 jaar5j -37,08%

donderdag 9 mei 2024, 13:00

Kwartaalcijfers (1ste kwartaal)

Royalty Pharma plc in het nieuws

Toon enkel gratis nieuws

9 januari 2023 · Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness · Persbericht

13 juli 2022 · Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value · Persbericht

30 juni 2022 · Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma · Persbericht

29 maart 2022 · Royalty Pharma Announces Charitable Alliance with The Leukemia & Lymphoma Society (LLS) To Advance Initiatives that Address Healthcare Disparities in Blood Cancer Care and Treatment · Persbericht

17 februari 2021 · Royalty Pharma Reports Q4 2020 and Full-Year Results · Persbericht

22 januari 2021 · Royalty Pharma to Announce Fourth-Quarter 2020 Financial Results on February 17, 2021 · Persbericht

8 januari 2021 · Royalty Pharma Announces 13% Dividend Increase · Persbericht

7 januari 2021 · Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 12 · Persbericht

Profiel Royalty Pharma plc

Gezondheidstechnologie

Medicinale en botanische productie

Website: www.royaltypharma.com

Hoofdzetel: New York, New York Verenigde Staten

CEO: Pablo Gerardo Legorreta

Werknemers: 92

Aandelen Royalty Pharma plc

Beurswaarde: 4,10 miljard USD

Effecten: 146,46 miljoen

Winst per aandeel (12 maand): PLUS

Koers-winstverhouding: PLUS

Beta: 0,65

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe